VolitionRx CEO now directly owns 2,554,847 VNRX shares

Rhea-AI Filing Summary

VolitionRx Ltd (VNRX) reported an insider share purchase by its President, CEO, and Director, Cameron John Reynolds. On 11/17/2025, he acquired 20,000 shares of common stock in an open market transaction at $0.35 per share. Following this purchase, he holds 2,554,847 common shares directly. In addition, there are 1,007,718 shares held indirectly through Concord International, Inc., where he is the majority shareholder and shares voting and dispositive control, and 34,076 shares held indirectly through his spouse.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reynolds Cameron John

(Last) (First) (Middle)

1489 WEST WARM SPRINGS ROAD

SUITE 110

(Street)

HENDERSON NV 89014

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		P		20,000	A	$0.35	2,554,847	D
Common Stock								1,007,718	I	By Concord International, Inc.(1)
Common Stock								34,076	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares of common stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.

Remarks:

	/s/ Cameron John Reynolds	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did VolitionRx (VNRX) report for Cameron John Reynolds?

VolitionRx reported that President, CEO, and Director Cameron John Reynolds purchased 20,000 shares of common stock on 11/17/2025 at a price of $0.35 per share.

How many VolitionRx (VNRX) shares does Cameron John Reynolds own directly after this transaction?

After the reported transaction, Cameron John Reynolds directly owns 2,554,847 shares of VolitionRx common stock.

What indirect holdings in VolitionRx (VNRX) are attributed to Cameron John Reynolds?

Indirectly, 1,007,718 shares are held through Concord International, Inc., where he is the majority shareholder and shares voting and dispositive control, and 34,076 shares are attributed through his spouse.

What is Cameron John Reynolds’ role at VolitionRx (VNRX)?

Cameron John Reynolds serves as President, Chief Executive Officer, and a Director of VolitionRx Ltd.

Was the VolitionRx Form 4 filed by a single reporting person?

Yes. The filing indicates that the Form 4 was filed by one reporting person, Cameron John Reynolds.

What does the Form 4 say about Concord International, Inc.’s VolitionRx shares?

The Form 4 explains that VolitionRx common stock held by Concord International, Inc. is attributed to Cameron John Reynolds because he is the majority shareholder and shares voting and dispositive control over those 1,007,718 shares.